[Experience with ciclesonide in patients with mild persistent bronchial asthma].
Experience with ciclesonide in patients with mild persistent bronchial asthma The study aimed to monitor the effectiveness and safety of the treatment with ciclesonide, administered once a day in a 160 microg dose, over a 3-month period, to a group of 100 patients diagnosed with mild persistent bronchial asthma with deterioration of problems after exercise. The results of the study prove significant positive effects of the preparation used. A significant improvement of FEV1 and PEF values was observed, as well as a statistically significant remission of both day and nocturnal symptoms of the disease, a significantly lower consumption of short-acting beta2-sympathomimetics, and an improvement of all evaluated data relating to the quality of life of the asthmatic patients. No adverse effects were registered.
Bartosíková
L
L
Univerzita Palackého, Lékarská fakulta, Ustav fyziologie, Olomouc Dům zdraví, Velké Meziricí. bartosil@tunw.upol.cz
Necas
J
J
Frána
L
L
Bartosík
T
T
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D011282:Pregnenediones / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D011282:Pregnenediones; C120481:ciclesonide